Remdesivir (Veklury)

CADTH recommends that Veklury be reimbursed by public drug plans for the treatment of COVID-19 in adults who are not hospitalized and have positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing and who are at high risk for progression to severe COVID-19, including hospitalization and death, if certain conditions are met. Veklury should only be covered to treat patients who meet the criteria used by each of the public drug programs for reimbursement of Paxlovid for the treatment of COVID-19 in adults. Treatment should be initiated as soon as possible and within 7 days of symptom onset. Veklury should only be reimbursed if treatment does not exceed 3 days, is not used in combination with any other antiviral medication for COVID-19 (including Paxlovid), and the cost is reduced.